Fed. Circ. Nixes Deal In Sun Pharma Eloxatin Suit
By Hilary Russ ( December 23, 2010, 8:19 PM EST) -- Sun Pharmaceutical Industries Inc. could be one step closer to selling a generic version of the colon cancer drug Eloxatin after convincing a federal appeals court to vacate and remand a settlement and injunction that a lower court had approved despite Sun's opposition....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.